Magic mushroom compound psilocybin tested in major depression trial
NCT ID NCT06308653
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This Phase 3 study tests whether a single 25 mg dose of synthetic psilocybin can reduce depression symptoms in 238 adults with major depressive disorder. Participants receive either psilocybin or a placebo, and their depression severity is measured over 43 days. The trial also looks at safety and how long any benefits last, with optional repeat doses over a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- psilocybin (synthetic, 25 mg capsule)
- What this could lead to
- If successful, this could point toward a new, single-dose treatment option for major depression that reduces symptoms for weeks or longer.
- What could go wrong
- This is a Phase 3 trial, but results are not yet available. The effect may be modest, not work for everyone, or have side effects like anxiety or nausea. Long-term benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AIM Trials, LLC
Plano, Texas, 75093, United States
-
Bronx Veterans Research Foundation at the James J. Peters VAMC
The Bronx, New York, 10468, United States
-
Cedar Clinical Research
Draper, Utah, 84020, United States
-
Cedar Clinical Research, Inc.
Murray, Utah, 84107, United States
-
CenExel iResearch, LLC
Decatur, Georgia, 30030, United States
-
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida, 32256, United States
-
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32801, United States
-
Clinical Trials of Texas, LLC
San Antonio, Texas, 78229, United States
-
Connecticut Mental Health Center, Yale University
New Haven, Connecticut, 06519, United States
-
Emory University
Atlanta, Georgia, 30329, United States
-
Global Medical Institutes, LLC; Princeton Medical Institute
Princeton, New Jersey, 08540, United States
-
Great Lakes Clinical Trials
Chicago, Illinois, 60640, United States
-
Innovative Clinical Research, Inc.
Lauderhill, Florida, 33319, United States
-
Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research
Baltimore, Maryland, 21224, United States
-
Kadima Neuropsychiatry Institute
La Jolla, California, 92037, United States
-
Mountain View Clinical Research
Denver, Colorado, 80209, United States
-
NYU Clinical & Translational Science Institute
New York, New York, 10016, United States
-
Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners
Santa Monica, California, 90404, United States
-
Preferred Research Partners, Inc.
Little Rock, Arkansas, 72211, United States
-
Preferred Research Partners-NWA, LLC
Fayetteville, Arkansas, 72703, United States
-
Psychedelic Science Institute
Santa Monica, California, 90404, United States
-
Seattle Neuropsychiatric Treatment Center
Bellevue, Washington, 98004, United States
-
Sunstone Medical PC
Rockville, Maryland, 20850, United States
-
University of Alabama Clinical Research Unit
Birmingham, Alabama, 35209, United States
-
University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center
Albuquerque, New Mexico, 87106, United States
-
VA Nebraska Western Iowa Health Care System
Omaha, Nebraska, 68105, United States
-
VA Portland Health Care System
Vancouver, Washington, 98661, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
West LA VA Medical Center - Mental Health Department
Los Angeles, California, 90073, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single dose of a new drug boost depression relief?
- Can a new pill ease depression without Add-Ons?
- Brain scans could make TMS for depression more precise
- Can brain training help depressed young adults stop ruminating?
- 45,000 students to be tracked: can we predict who will fall into depression?
- New depression pill BI 1569912 put to the test in 225-Person trial